MUMBAI, India, June 26 -- Intellectual Property India has published a patent application (202647070944 A) filed by Novo Nordisk As on June 08, 2026, for Tri-Agonists Of The Glp-1, Gip, And Amylin Receptors.
Inventors include Kruse, Thomas; Lau, Jesper F.; Frich, Camilla Kaas; Madsen, Charlotte Stahl; Haxvig, Christina Sophie; and Behrens, Carsten.
The application for the patent was published on June 19, 2026, under issue no. 25/2026.
Abstract: The present invention relates to a GLP-1-/GIP-/amylin-receptor tri-agonist. This GLP-1-/GIP-/amylin-receptor tri-agonist may have improved pharmacokinetic properties and may be suitable for once weekly administration. The invention also relates to pharmaceutical compositions comprising such a GLP-1-/GIP-/amylin- receptor tri-agonist. The tri-agonist and pharmaceutical compositions comprising it may be used as a medicament for the treatment of subjects with overweight, obesity and associated co-morbidity.
Disclaimer: Curated by HT Syndication.
